An international research team has uncovered a surprising ally in the fight against insulin resistance and type 2 diabetes: a ...

Colibactin is a powerful toxin produced by Escherichia coli and other bacteria living in the human gut. This highly unstable ...

Antibiotics are no longer able to treat infections as effectively as they once did because many pathogens have developed ...

A new experimental antibiotic has stunned researchers by wiping out dangerous bacteria at concentrations roughly two orders ...

The market capitalization of the company has soared by Rs 5,400 crore in these two days of sharp gains to Rs 25,493 crore.

India expands lab and surveillance networks to fight rising antimicrobial resistance, as experts warn of growing drug-resistant infections and call for stronger stewardship and coordinated global ...

Researchers have designed a chemical phototherapy tool that when exposed to blue light damages an enzyme found in ...

Auto, telecom, and PSU stocks fuel midday action as M&M, Lenskart, and Tejas Networks jump. Market remains mixed with ...

Wockhardt shares surge as US FDA accepts first-ever NDA from an Indian pharma company for new antibiotic Zaynich, aimed at ...

Wockhardt zoomed 18.01% to Rs 1455.70 after the company said that the United States Food and Drug Administration (US FDA) has formally accepted the new drug application (NDA) for its novel, ...

Zaynich targets complicated urinary tract infections (cUTIs) caused by multi-drug resistant (MDR) gram-negative bacteria.

The study analyzed a specific sample of used products that were collected from Virginia schools between 2024 and 2025.